Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages

Gut

Volumn 39, Issue 3, 1996, Pages 475-478

  Ljubuncic, P ^a   Fuhrman, B ^b   Oiknine, J ^b   Aviram, M ^a,b   Bomzon, A ^a,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antioxidant; Deoxycholic acid; Macrophages; Ursodeoxycholic acid

Indexed keywords

DEOXYCHOLIC ACID; REACTIVE OXYGEN METABOLITE; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; LIPID ANALYSIS; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029825946     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.3.475     Document Type: Article

References (44)

1. Johnston RBJ. Monocytes and macrophages. N Engl J Med 1988; 318: 747-52.
2. Rosser BG, Gores GJ. Liver cell necrosis: Cellular mechanisms and clinical implications. Gastroenterology 1995; 108: 252-75.
3. Freeman BA, Crapo JD. Biology of disease. Free radicals and tissue injury. Lab Invest 1982; 47: 412-6.
4. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991; 91 (suppl3C): 14s-22s.
5. Beckman JS, Beckman TW, Chen J, Marshall PA, Breeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4.
6. Noronha-Dutra AA, Epperlein MM, Woolf N. Reaction of nitric oxide with hydrogen peroxide to produce potentially cyctotoxic singlet oxygen as a model for nitric oxide-mediated killing. FEBS Lett 1993; 1: 59-62.
7. Schmuckler DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990; 12: 1216-21.
8. Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104: 1736-44.
9. DeRubertis FR, Craven PA. Relationship of bile salt stimulation of colonic epithelial phospholipid turnover and proliferative activity: role of activation of protein kinase C. Prev Med 1987; 16: 572-9.
10. Krähenbühl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology 1994; 19: 471-9.
11. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Roles of ATP depletion and cytosolic free calcium. J Clin Invest 1993; 92: 17-24.
12. Sokol RJ, Devereaux M, Khandwala R, O'Brien K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology 1993; 17: 869-81.
13. Krähenbühl S, Talos C, Fisher S, Reichen J. Ursodeoxycholate decreases mitochondrial toxicity and membrane incorporation of lipophilic bile acids. Hepatology 1993; 18: 306A.
14. Krähenbühl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: Dose-response study in isolated rat liver mitochondria. Hepatology 1994; 20: 1595-601.
15. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994; 29: 1-15.
16. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: A mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995; 272: 930-8.
17. Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnus F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis. Lancet 1987; i: 834-6.
18. Leuschner U, Fischer H, Kurtz W. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind study. Gastroenterology 1989; 97: 1268-74.
19. Oka H, Toda G, Ikeda Y. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 1990; 25: 774-80.
20. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54.
21. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
22. Lim AG, Northfield TC. Ursodeoxycholic acid and primary biliary cirrhosis. BMJ 1994; 309: 491-2.
23. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
24. Poupon RE, Poupon R, Balkau B, UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342-7.
25. Fuhrman B, Oiknine J, Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis 1994; 111: 65-78.
26. Draper HH, Hadley M. Malondialdehyde determination as an index of lipid peroxidation. Methods Enzymol 1990; 186: 421-31.
27. Holley AE, Cheeseman KH. Measuring free radical reactions in vivo. Br Med Bull 1993; 49: 494-505.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265 75.
29. Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther 1995; 66: 1-15.
30. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res 1989; 30: 719-30.
31. Ostrow JD. Metabolism of bile salts in cholestasis in humans. In: Tavoloni N, Berk PD, eds. Hepatic transport and bile secretion: physiology and pathophysiology. New York: Raven Press, 1993: 673 712.
32. Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, et al. Ursodeoxycholic acid-induced changes in plasma and urinary bile acids in patients with primary biliary cirrrhosis. Hepatology 1990; 12: 492 7.
33. Chrétien Y, Poupon R, Gherardt MF, Chazouilleres O, Labbe D, Myara A, Trivin F. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut 1989; 30: 1110-5.
34. Crosignani A, Podda M, Battezzati PM, Bertolini F, Zuin M, Watson D, Setchell KDR. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000-7.
35. Leuschner U, Güldütuna S, Imhof M, Hübner K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid after four to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994; 21: 624-33.
36. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100: 203 11.
37. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993; 104: 1865-70.
38. Jazrawi RP, De Caestecker JS, Goggin PM, Britten AJ, Joseph AEA, Maxwell JD, Northfield TC. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106: 134-42.
39. Gurantz D, Schteingart CD, Hagey LR, Steinbach JH, Grotmol T, Hofmann AF. Hypercholeresis induced by unconjugated bile acid infusion correlates with recovery in bile of unconjugated bile acids. Hepatology 1991; 13: 540-50.
40. 3-rich hypercholeresis. An analysis based on quantitative acid-base chemistry. J Hepatol 1992; 14: 118 26.
41. Elsing C, Sagesser H, Reichen J. Ursodeoxycholate-induced hypercholeresis in cirrhotic rats: further evidence for cholehepatic shunting. Hepatology 1994; 20: 1048-54.
42. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immue responses. Hepatology 1992; 16: 358 64.
43. Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vivo study on human peripheral blood mononuclear cells. Hepatology 1993; 18: 165-72.
44. Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994; 106: 1333-41.